10-Q: uniQure Faces AMT-130 BLA Delay, Boosts Cash Reserves

uniQure N.V. reported mixed Q3 2025 results, with a significant increase in cash from recent offerings, but a major setback in its lead Huntington's disease program, AMT-130, due to FDA feedback.

Summary

• Net loss for the three months ended September 30, 2025, was $80.5 million, compared to $44.4 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $161.9 million, an improvement from $166.3 million for the same period in 2024.
• Total revenues for Q3 2025 increased to $3.7 million from $2.3 million in Q3 2024, primarily due to higher license revenues from HEMGENIX.
• Total revenues for the nine months ended September 30, 2025, decreased to $10.5 million from $21.9 million in the same period of 2024, mainly due to the absence of contract manufacturing and collaboration revenues after the Lexington Transaction.
• Cash and cash equivalents and investment securities significantly increased to $694.2 million as of September 30, 2025, from $367.5 million as of December 31, 2024.
• The company believes its existing cash resources are sufficient to fund operations into 2029.
• The FDA no longer agrees that Phase I/II study data for AMT-130, using an external control, may be adequate for a Biologics License Application (BLA) submission, making the timing of submission unclear.
• AMT-130's pivotal Phase I/II study met its primary endpoint, showing a statistically significant 75% slowing of disease progression (cUHDRS) at 36 months in high-dose patients compared to an external control.
• Enrollment in the AMT-162 (SOD1-ALS) Phase I/II clinical trial was voluntarily paused following a dose-limiting toxicity observed in one patient in the second cohort.
• The company completed two follow-on public offerings in January and September 2025, raising net proceeds of $70.1 million and $323.7 million, respectively.
• The Hercules loan facility was amended in September 2025, providing access to an additional $125.0 million, subject to BLA approval for AMT-130 and Hercules' approval for tranches.
• The Dutch tax authorities determined that the $375.0 million upfront payment from the Royalty Financing Agreement is taxable income in 2023, resulting in a $7.5 million current tax expense and $1.1 million related interest expense for Q3 2025.
• Accumulated deficit reached $1,291.9 million as of September 30, 2025.

Sentiment

Score: 3

Explanation: The significant regulatory setback for the lead program AMT-130, despite positive clinical data, creates substantial uncertainty and delays. While the company has a strong cash position from recent capital raises, the core business's path to market for its most advanced candidate is now significantly challenged. The pause in another clinical trial (AMT-162) further adds to the negative sentiment, outweighing the improved cash runway.

Positives

• AMT-130's pivotal Phase I/II study met its primary endpoint, demonstrating a statistically significant 75% slowing of Huntington's disease progression (cUHDRS) at 36 months in high-dose patients.
• A key secondary endpoint for AMT-130, Total Functional Capacity (TFC), also showed a statistically significant 60% slowing of disease progression at 36 months in high-dose patients.
• AMT-130 received Breakthrough Therapy designation from the FDA in April 2025, and previously RMAT, Orphan Drug, and Fast Track designations.
• Cash and cash equivalents and investment securities increased significantly to $694.2 million as of September 30, 2025, from $367.5 million at year-end 2024, providing a cash runway into 2029.
• Successful follow-on public offerings in January and September 2025 raised substantial capital ($70.1 million and $323.7 million net proceeds, respectively).
• The Hercules loan facility was amended, providing access to an additional $125.0 million, contingent on AMT-130 BLA approval and other conditions.
• AMT-191 (Fabry disease) showed sustained increases in α-galactosidase A enzyme activity (27to 208-fold above normal range) in the first dose cohort, with a manageable safety profile.
• AMT-260 (MTLE) completed enrollment of the first three patients in the first cohort, allowing for expansion and initiation of the second cohort after positive IDMC review.

Negatives

• The FDA currently no longer agrees that data from the Phase I/II studies of AMT-130 in comparison to an external control may be adequate to provide primary evidence for a BLA submission, making the timing of BLA submission unclear.
• Net loss for the three months ended September 30, 2025, increased to $80.5 million from $44.4 million in the prior year period.
• Enrollment in the AMT-162 (SOD1-ALS) Phase I/II clinical trial was voluntarily paused due to a dose-limiting toxicity (SAE related to AMT-162) observed in one patient.
• Total revenues for the nine months ended September 30, 2025, decreased by $11.4 million compared to the same period in 2024, primarily due to the divestment of commercial manufacturing activities.
• Interest income decreased by $1.4 million for Q3 2025 and $6.0 million for YTD 2025, primarily due to lower balances of cash and investment securities compared to the prior year.
• The company recognized a $5.7 million loss in Q3 2025 related to an increase in the fair value of the liability related to pre-funded warrants.
• The Dutch tax authorities' position on the $375.0 million royalty upfront payment as taxable income in 2023 resulted in a $7.5 million current tax expense and $1.1 million related interest expense for Q3 2025.

Risks

• Dependence on the success of AMT-130; failure in clinical development, regulatory approval, manufacturing, or commercialization could adversely affect the business.
• Potential for future delays or impediments in clinical trials, or failure to demonstrate safety and efficacy of product candidates.
• Early-stage clinical trial progress may not be predictive of long-term efficacy in late-stage trials, or for other product candidates.
• Inability to successfully commercialize product candidates or significant delays in doing so could materially harm the business.
• Approved gene therapies may fail to achieve sufficient market acceptance by physicians, patients, and third-party payers.
• Interim, topline, or preliminary clinical trial results may change as more data become available or due to regulatory audit/review.
• Uncertainty regarding when or if marketing approval will be obtained for product candidates.
• Disruptions at the FDA and other government agencies could hinder timely guidance and approval of product candidates.
• Risks associated with the marketing approval process are heightened for gene therapies due to their novel status.
• Inability to obtain and maintain benefits of specialized regulatory pathways (e.g., accelerated approval, RMAT, Breakthrough Therapy designation).
• Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception or affect business/approvals.
• Business development and strategic initiatives, acquisitions, partnerships, or collaborations may not achieve intended benefits or goals.
• Inability to obtain rights from external parties to new product candidates/technologies or secure partnerships.
• Gene therapies are complex, expensive, and difficult to manufacture; third-party manufacturers (like Genezen) could experience capacity, production, or technology transfer challenges.
• Manufacturing of products and product candidates is subject to significant government regulations and approvals; reliance on third parties may lead to non-compliance.
• Continued net losses and expectation to incur losses in the future, with no guarantee of achieving or maintaining profitability.
• Future changes in legal and regulatory requirements may materially impact results of operations.
• Volatility and substantial fluctuations in the market price of ordinary shares.
• Future success depends on ability to retain key executives, technical staff, and other employees and to attract, retain, and motivate qualified personnel.
• Substantial competition from larger pharmaceutical and biotechnology companies, academic institutions, and government agencies.
• Certain product candidates may require medical devices for administration/diagnostics, potentially leading to additional regulatory requirements and delays.
• Uncertainty related to insurance coverage, pricing, and reimbursement for product candidates.
• Limited addressable market for target indications and potential for single-administration therapies present challenges for pricing and reimbursement.
• Ethical, legal, and social issues associated with genetic testing may reduce demand for gene therapy products.
• Risks associated with international operations if commercializing outside the U.S.
• Product liability lawsuits could cause substantial liabilities and limit commercialization.
• Healthcare legislative and regulatory reform measures may have a material adverse effect on financial operations.
• Existing and future indebtedness could adversely affect the ability to operate the business.
• Unstable market and economic conditions (inflation, tariffs, interest rates, geopolitical issues) may negatively impact the business.
• Failure to maintain an effective system of internal controls could lead to inaccurate reporting or fraud.
• Internal computer systems or those of third parties may fail or suffer security breaches, disrupting business and development programs.
• If securities or industry analysts cease to publish or publish inaccurate/unfavorable research, share price and trading volume could decline.
• Failure to achieve projected development and financial goals in announced timeframes could delay commercialization and reduce share price.
• Environmental sustainability and social initiatives may impose additional costs and risks.

Future Outlook

The company believes its existing cash and cash equivalents and investment securities will be sufficient to fund projected operating expenses into 2029, including ongoing clinical trials for AMT-130, AMT-162, AMT-191, and AMT-260, and potential expenses for AMT-130 marketing authorizations. However, the timing of the BLA submission for AMT-130 is now unclear following FDA feedback, which could impact future funding availability from the Hercules loan facility. The company may require additional funding sooner than expected and may pursue public equity offerings, collaborations, or other arrangements.

Management Comments

• We believe that the consistently favorable results in functional, motor and cognitive endpoints at 36 months observed in the high-dose group of AMT-130, compared to the variable trends observed in the low-dose group, reflect a dose-dependent response to AMT-130.
• Based on discussions at the pre-BLA meeting, we believe that the FDA currently no longer agrees that data from the Phase I/II studies of AMT-130 in comparison to an external control, as per the prespecified protocols and statistical analysis plans shared with the FDA in advance of the analyses, may be adequate to provide the primary evidence in support of a BLA submission.

Industry Context

The gene therapy industry is characterized by high development costs, long timelines, and significant regulatory hurdles. uniQure's focus on rare and devastating diseases aligns with a key area of gene therapy innovation. The FDA's cautious stance on novel gene therapies, particularly regarding reliance on external controls for pivotal evidence, reflects broader regulatory scrutiny in the sector. The competitive landscape is intense, with many companies pursuing similar therapeutic approaches, which could impact patient enrollment for trials and market share for approved products. The potential for single-administration, curative treatments presents unique challenges for pricing and reimbursement models, as payers may be reluctant to provide significant upfront reimbursement without long-term efficacy data.

Comparison to Industry Standards

• The FDA's stance on AMT-130's BLA submission, requiring more than Phase I/II data with external controls, indicates a higher bar for regulatory approval for gene therapies, especially for novel investigational products and rare diseases, compared to what the company had anticipated or aligned on previously. This contrasts with some accelerated approval pathways that might accept surrogate endpoints or smaller datasets.
• The voluntary pause in AMT-162 enrollment due to a dose-limiting toxicity is a common setback in early-stage gene therapy development, where safety profiles are still being established. Similar events have occurred across the industry, highlighting the inherent risks of novel therapeutics.
• The significant cash reserves ($694.2 million) and projected runway into 2029, bolstered by recent public offerings, position uniQure favorably compared to many smaller biotech firms that frequently face liquidity challenges, especially given the capital-intensive nature of gene therapy development.

Corporate Governance

Related Party Transactions

• The company has an investment in a convertible promissory note with a nominal amount of $12.5 million, bearing interest at 8.0% per annum, maturing in October 2029. The balance was $14.4 million as of September 30, 2025.
• The company entered into a Royalty Financing Agreement with HemB SPV, L.P. in May 2023, receiving an upfront payment of $375.0 million in exchange for rights to the lowest royalty tier on CSL Behring's worldwide net sales of HEMGENIX. The company expects to pay $843.8 million to the Purchaser over the term.

Stakeholder Impact

• **Shareholders**: Potential for significant share price volatility due to the AMT-130 regulatory setback. Dilution from recent and potential future equity offerings. Long-term value creation is now more uncertain due to delays in the lead program.
• **Patients (Huntington's Disease)**: Delayed access to a potentially disease-modifying therapy (AMT-130) due to regulatory hurdles, impacting those with an urgent unmet medical need.
• **Patients (SOD1-ALS)**: Enrollment pause in AMT-162 trial due to safety concerns means delayed or halted access to a potential treatment.
• **Employees**: Continued focus on strategic priorities and cost conservation, following a significant workforce reduction in 2024, may create uncertainty. However, share authorization for incentive plans aims to retain talent.
• **Regulatory Authorities (FDA)**: Continued engagement and potential need for additional studies for AMT-130 will require significant resources and collaboration.
• **Creditors (Hercules Capital)**: The ability to draw down additional loan tranches is now contingent on AMT-130 BLA approval, introducing risk to future funding availability from this source.
• **CSL Behring**: The company remains contractually obligated to CSL Behring for HEMGENIX supply, now relying on Genezen for manufacturing, which introduces third-party risk.

Next Steps

• Receive final meeting minutes from the FDA regarding the pre-BLA meeting for AMT-130 within 30 days of the October 2025 meeting.
• Complete patient dosing in the fourth cohort of the AMT-130 study before year-end 2025.
• Continue to collect and evaluate data from the five patients dosed in the paused EPISOD1 (AMT-162) trial.
• Potentially pursue additional studies or trials for AMT-130 as required by the FDA to support a BLA submission.
• Monitor and potentially draw down additional tranches from the Hercules loan facility upon achievement of BLA approval for AMT-130 and other conditions.
• Potentially utilize the at-the-market (ATM) offering program to raise additional capital.
• Address the Dutch tax authorities' position on the $375.0 million upfront payment from the Royalty Financing Agreement for the 2023 tax filing.

Key Dates

Recommendation

The significant regulatory setback for AMT-130, uniQure's lead program, creates substantial uncertainty regarding its path to market and future revenue generation. While the company has significantly bolstered its cash reserves, providing a runway into 2029, this capital is now needed to navigate an unclear regulatory path, potentially requiring additional, costly trials. The pause in the AMT-162 trial due to a dose-limiting toxicity further adds to clinical development risks. The positive clinical data for AMT-130 and AMT-191 are encouraging, but the FDA's current stance on the BLA submission for AMT-130 is a major negative catalyst. Investors should hold, awaiting clarity on the FDA's final feedback and the company's revised development strategy for AMT-130, as the immediate future presents heightened risk and an extended timeline for its most valuable asset.

Keywords

Gene Therapy, Huntington's Disease, AMT-130, FDA, Biologics License Application, Clinical Trials, Rare Diseases, Biotechnology, Pharmaceutical, SEC Filing, 10-Q, Financial Results, Capital Raise, Orphan Drug, Breakthrough Therapy, AMT-162, SOD1-ALS, AMT-191, Fabry Disease, AMT-260, MTLE, HEMGENIX